News and Announcements
iFAST Singapore Launches FSMOne
- Published December 08, 2016 3:10PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
8th December 2016 – iFAST Corporation
iFAST Financial Pte Ltd (“iFAST Singapore”), the Singapore subsidiary of SGX-ST Mainboard-listed iFAST Corporation Ltd. (“iFAST Corp”), has launched the FSMOne account, on its Business-to-Consumer (B2C) platform, Fundsupermart.com (“FSM”) which caters to Do-It-Yourself (DIY) investors.
FSMOne allows the investors community in Singapore to invest seamlessly and in a transparent way, in multiple investment products including funds, bonds and insurance products, as well as new investment products and services including roboadvisory portfolios known as FSM MAPS (My Assisted Portfolio Solution), stocks and Exchange Traded Funds (ETFs).
To view the full announcement, please click on the button below.
Company Updates
The $3 Billion Blind Spot: How Venstra Medical is using “Collapsible” Physics to Challenge a Global Med-Tech Giant
In the high-stakes theater of the cath lab, cardiogenic shock is the ultimate emergency. Now, a PhD in fluid mechanics and a frontline cardiologist are deploying a “collapsible” breakthrough to disrupt a 30-year monopoly. The Engineer’s Mission For Dr. Martin Cook, the stakes of medical engineering aren’t measured in blueprints, but in heartbeats. A PhD […]
The Blue-Collar ‘Muscle’ Behind Australia’s $100bn Pipeline: One Key Resources Eyes Expansion
As Australia faces a “perfect storm” of low unemployment and an ambitious $100bn project pipeline, One Key Resources MD Ben Lewis explains why the next five years will be defined by the “muscle power” required to deliver the nation’s energy and infrastructure goals.
Off-the-Shelf, On-the-Money: How a Melbourne Biotech is Expanding its Oncology Platform to Endometriosis
Cartherics is bridging the gap in women’s health by utilising iPSC-derived Natural Killer cells to target both ovarian cancer and endometriosis. With a proprietary manufacturing facility and a lead candidate heading to Phase 1 trials, the company is industrialising cell therapy to solve a multi-billion dollar unmet need.
Backed By Leading Investment Groups and Family Offices
